Explore 3 Stock Ideas & Industry Insights Download Free Report

General News

What Demand Signals Can BA (NYSE:BA), KO (NYSE:KO), V (NYSE:V) and NUE (NYSE:NUE) Send Before the Fed?

Boeing (NYSE:BA) releases third-quarter figures before the market opens Tuesday, October 27, and holds a 10:30 a.m. ET call. Analysts project a loss of approximately USD 0.20-USD 0.26 per share, much smaller than the USD 7.47 deficit a year earlier. Revenue forecasts run from …

Vinay Lochav | 26 October 2026

Can HOOD (NASDAQ:HOOD), SOFI (NASDAQ:SOFI) and COIN (NASDAQ:COIN) Pass Their Retail-Activity Tests?

Tuesday trading is followed by Robinhood Markets (NASDAQ:HOOD) results on October 27; its video discussion starts at 5:00 p.m. ET. Consensus stands at USD 0.55-USD 0.56 per share versus USD 0.61 a year earlier. Analysts put revenue between USD 1.42 billion and USD 1.44 …

Vinay Lochav | 26 October 2026

How Are Payouts and Capacity Shaping SKHY (NASDAQ:SKHY), STX (NASDAQ:STX) and SNDK (NASDAQ:SNDK)?

SK hynix (NASDAQ:SKHY) is reviewing shareholder-return choices after selling Kioxia shares, according to October 26 press reports. A special dividend could reach 16 trillion won, equivalent to roughly USD 12 billion-USD 12.1 billion, but the company said no amount was settled. Its plan is …

Vinay Lochav | 26 October 2026

Could IWM (NYSEARCA:IWM) Keep Rising if ServiceNow (NYSE:NOW) or CrowdStrike (NASDAQ:CRWD) Disappoints?

A Wednesday, October 28, 2026 report will test ServiceNow against roughly USD 4.09 billion of revenue consensus and management's 19.5% cRPO growth guide.

Vinay Lochav | 26 October 2026

Could Corcept (NASDAQ:CORT) and Moderna (NASDAQ:MRNA) Foreshadow Eli Lilly's (NYSE:LLY) Earnings Risk?

Eli Lilly's Thursday, October 29, 2026 report faces USD 88.68 billion of full-year revenue consensus, above a company range that starts at USD 85 billion and ends at USD 87 billion, after the stock lost roughly 3.3% Friday.

Vinay Lochav | 26 October 2026

Can Earlier Cancer Use Reprice Amgen (NASDAQ:AMGN), Summit (NASDAQ:SMMT) and Johnson & Johnson (NYSE:JNJ) After ESMO?

Akeso's Summit-partnered ivonescimab regimen delivered 14.9 months of median survival versus 12.1 months for an Imfinzi regimen in advanced biliary tract cancer at ESMO 2026.

Vinay Lochav | 26 October 2026

Why Did Lycia (NASDAQ:LYCA) and Zymeworks (NASDAQ:ZYME) Rise While Tango (NASDAQ:TNGX) Lost 16%?

Lycia increased its IPO to USD 317.5 million and priced shares at USD 18 before the stock approached USD 30 on October 23, 2026, for measured gains of roughly 47% to 67%.

Vinay Lochav | 26 October 2026

Could American Express (NYSE:AXP) Signal a Spending Trap for Mastercard (NYSE:MA) and Visa (NYSE:V)?

Visa's fiscal fourth-quarter report follows Tuesday's close on October 27, 2026. Expected EPS begins at USD 3.43 and tops out at USD 3.44 versus USD 2.98 last year after a 10% monthly rise to a record.

Vinay Lochav | 26 October 2026

Can Netflix (NASDAQ:NFLX), Nike (NYSE:NKE), Newell Brands (NASDAQ:NWL) and Deckers Outdoor (NYSE:DECK) Turn Setbacks Into Durable Growth?

Nike (NYSE:NKE) has given investors a date for its next turnaround update, but not the substance. The athletic footwear and apparel business announced after the October 23, 2026 close that its 2026 Investor Day will take place on Tuesday, November 17. It provided no …

Vinay Lochav | 26 October 2026

What Do Diverging Broker Views Mean for SpaceX (NASDAQ:SPCX), Allegion (NYSE:ALLE), EWY (NYSEARCA:EWY) and Cboe (CBOE:CBOE)?

Allegion (NYSE:ALLE) moved 1.39% higher on October 23, 2026 after a research firm upgraded the lock and electronic-access supplier to Buy and increased a USD 200 target. The argument centered on unit growth as demand recovers. That gain stood apart from a weak session …

Vinay Lochav | 26 October 2026
Support

Hi! How can we help you today?

Loading…